REG - Roquefort Theraptcs. - Director/PDMR Shareholding

Roquefort TherapeuticsAnnouncement

19/01/2022 13:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220119:nRSS9862Ya&default-theme=true

RNS Number : 9862Y  Roquefort Therapeutics PLC  19 January 2022

 

 

19 January 2022

 

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

 

Director/PDMR Shareholding

 

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company
focused on early-stage opportunities in the biotechnology sector, advises that
Stephen West, Executive Chairman has purchased ordinary shares in the Company
in the market, as detailed below:

 

               Number of Ordinary Shares  Average Price Paid Per Share  Total Consideration Paid

 Name
 Stephen West  150,000                    10.36 pence                   £15,542.10

 

Following the above purchase of shares, Mr West holds interests in the
following Company securities:

 

               Number of Ordinary Shares Held  % of Issued Share Capital  Number of Warrants Held

 Name
 Stephen West  4,550,000                       6.33 %                     7,500,000

 

4,399,000 of Mr West's shares are held in the name of Cresthaven Investments
Pty Ltd ATF the Bellini Trust.

 
Enquiries:
 Roquefort Therapeutics plc
 Stephen West (Chairman)                    +44 (0)20 3290 9339

 Buchanan (Public Relations)

 Ben Romney / Jamie Hooper / George Beale   +44 (0)20 7466 5000

 Optiva Securities Limited (Broker)
 Christian Dennis                           +44 (0)20 3411 1881

 

For further information on Roquefort Therapeutics, please visit
www.roquefortinvest.com (http://www.roquefortinvest.com) and
@RoquefortTherap on Twitter.

 

LEI: ‎254900P4SISIWOR9RH34

 

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech company
developing products through the pre-clinical phase prior to partnering or
selling to big pharma.  The Company's wholly owned subsidiary, Lyramid Pty
Ltd ("LYRAMID"), is a pre-clinical biotech company focused on developing first
in class Midkine inhibiting RNA therapeutics drugs for the treatment of
cancer, chronic inflammatory, autoimmune disorder and COVID-19.  Recent
progress within mRNA therapeutics has led to a reduction in drug development
timelines and costs, increasing the chance of early value creation.

 

Through extensive research resulting in validation through publication in over
1,000 scientific journals, Lyramid has identified the potential to exploit the
broad therapeutic potential of Midkine for a number of clinical indications of
unmet needs. Lyramid holds the largest global IP portfolio on Midkine. The
Midkine blocking drug development markets have significant global market
potential (in the multi-billion dollars). LYRAMID's pre-clinical programme is
currently underway with an initial focus on cancer (including immunotherapy
resistance) and COVID-19.

 

This announcement contains inside information for the purposes of Article 7 of
the UK version of Market Regulation (EU) No 596/2014 on Market Abuse as it
forms part of UK domestic law by virtue of the European Union (Withdrawal) Act
2018, as amended ("UK MAR").

The notification below, made in accordance with the requirements of the UK
MAR, provides further detail:

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

 1   Details of the person discharging managerial responsibilities / person closely
     associated
 a)  Name                                                         Stephen West
 2   Reason for the notification
 a)  Position/status                                              Executive Chairman
 b)  Initial notification /Amendment                              Initial
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Roquefort Therapeutics plc
 b)  LEI                                                          254900P4SISIWOR9RH34
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary shares of £0.01 par value

     Identification code

                                                                  ISIN: GB00BMDQ2T15
 b)  Nature of the transaction                                    Purchase of 150,000 ordinary shares
 c)  Price(s) and volume(s)                                       Price(s)                     Volume(s)
                                                                  10.31 pence per share        100,000

                                                                  10.46 pence per share          50,000
 d   Aggregated information

     - Aggregated volume                                          -       150,000

     - Price                                                      -       10.36p
 e)  Date of the transactions                                     19 January 2022
 f)  Place of the transactions                                    London Stock Exchange (XLON); Main Market

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBDGDBUUBDGDC